SEC Form 3 FORM 3

## UNITED STATES SECURITIES AND EXCHANGE

COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden hours per response: 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	013		The investment Company	ACLU	1340					
1. Name and Address of Reporting Pers <u>VV Manager II, LLC</u>	Requirir	of Event g Statement Day/Year) 2020	3. Issuer Name and Ticker or Trading Symbol <u>Dyne Therapeutics</u> , Inc. [ DYN ]							
(Last) (First) (Middle 40 BROAD STREET, SUITE 20	)		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)				5. If Amendment, Date of Original Filed (Month/Day/Year)			
(Street)			Director X 10% O Officer (give Other ( title below) below)			(specify	6. Ir (Ch	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person		
BOSTON MA 02109								X Form filed by More than One Reporting Person		
(City) (State) (Zip)	Table I N	on Donium		ofi old						
1. Title of Security (Instr. 4)		on-Deriva	tive Securities Ben 2. Amount of Securities	1	3. Owne		4. Na	ture of Indire	ct Beneficial	
		Beneficially Owned (Ins 4)				Ownership (Instr. 5)				
			e Securities Benefi ants, options, conv							
1. Title of Derivative Security (Instr. 4	) 2. Date Exerce Expiration D (Month/Day/	ate	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)			4. Convers or Exerc Price of	cise	ise Form: Direct (D) /e or Indirect	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title		ount or ober of res	Derivative Security				
Series B Preferred Stock	(1)	(1)	Common Stock	2,08	87,130	(1)		Ι	See footnote <sup>(2)(3)</sup>	
Series B Preferred Stock	(1)	(1)	Common Stock	57	,916	(1)		Ι	See footnote <sup>(4)</sup>	
1. Name and Address of Reporting Person <u>VV Manager II, LLC</u> (Last) (First)	(Middle)	_								
40 BROAD STREET, SUITE 20	1									
(Street) BOSTON MA	02109									
(City) (State)	(Zip)									
1. Name and Address of Reporting Personal Vida Ventures II, LLC	son <sup>*</sup>									
(Last) (First) 40 BROAD STREET, SUITE 20	(Middle) 1									
(Street) BOSTON MA	02109									
(City) (State)	(Zip)									
1. Name and Address of Reporting Per- VIDA VENTURES II-A, J										
(Last) (First)	(Middle)									

40 BROAD STREET, SUITE 201							
(Street) BOSTON	MA	02109					
(City)	(State)	(Zip)					

## Explanation of Responses:

1. The Series B Preferred Stock is convertible into common stock on a 3.3169-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

2. The shares are held directly by Vida Ventures II, LLC ("Vida II"). VV Manager II, LLC ("VV Manager II") is the manager of Vida II. Arie Belldegrun, Fred Cohen, and Leonard Potter are the members of the management committee of VV Manager II (the "Management Committee") and Stefan Vitorovic, Arjun Goyal, Helen Kim, Rajul Jain, and Joshua Kazam are the members of the investment committee of VV Manager II (the "Investment Committee").

3. (Continued from footnote 2) Each of the Management Committee, the Investment Committee and the respective members thereof may be deemed to share voting and dispositive power over the shares held by Vida II. VV Manager II, the Management Committee, the Investment Committee and each member of each of the Management Committee and Investment Committee disclaims beneficial ownership over the securities held of record by Vida II and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.

4. The shares are held directly by Vida Ventures II-A, LLC ("Vida II-A"). VV Manager II is the manager of Vida II-A. Each of the Management Committee, the Investment Committee and the respective members thereof may be deemed to share voting and dispositive power over the shares held by Vida II-A. VV Manager II, the Management Committee, the Investment Committee and each member of each of the Management Committee and Investment Committee disclaims beneficial ownership over the securities held of record by Vida II-A and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.

## **Remarks:**

/s/ Vida Ventures II, LLC By: VV Manager II, LLC, its Manager, By: /s/ Stefan 09/16/2020 Vitorovic, its Managing Director /s/ Vida Ventures II-A, LLC By: VV Manager II, LLC, its Manager, By: /s/ <u>09/1</u>6/2020 Stefan Vitorovic, its Managing Director /s/ VV Manager II, LLC By: /s/ Stefan Vitorovic, its 09/16/2020 Managing Director \*\* Signature of Reporting Date Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.